NISSAN CHEM IND/ADR (OTCMKTS:NNCHY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both mid-cap basic materials companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.
Earnings & Valuation
This table compares NISSAN CHEM IND/ADR and Hikma Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NISSAN CHEM IND/ADR||$1.75 billion||3.90||$244.28 million||$1.63||28.04|
|Hikma Pharmaceuticals||$2.07 billion||2.66||$282.00 million||$1.38||16.59|
This table compares NISSAN CHEM IND/ADR and Hikma Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NISSAN CHEM IND/ADR||N/A||N/A||N/A|
Risk & Volatility
NISSAN CHEM IND/ADR has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.
This is a breakdown of current recommendations for NISSAN CHEM IND/ADR and Hikma Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NISSAN CHEM IND/ADR||1||0||0||0||1.00|
NISSAN CHEM IND/ADR pays an annual dividend of $0.26 per share and has a dividend yield of 0.6%. Hikma Pharmaceuticals does not pay a dividend. NISSAN CHEM IND/ADR pays out 16.0% of its earnings in the form of a dividend.
Hikma Pharmaceuticals beats NISSAN CHEM IND/ADR on 6 of the 10 factors compared between the two stocks.
About NISSAN CHEM IND/ADR
Nissan Chemical Corporation engages in chemicals, performance materials, agricultural chemicals, pharmaceuticals, and advanced materials and planning businesses in Japan and internationally. Its chemical products include MELAMINE, an adhesive agent; high purity chemicals; AdBlue, a urea solution; FINEOXOCOL, a saturated fatty alcohol and acid; ammonia, sulfuric, and nitric acid; TEPIC, an epoxy compound; Melamine Cyanurate, a flame retardant; Nissan Reishi, a health food; phenylphosphonic acid, a surface modifier; HI-LITE, a chlorinated isocyanulate; and OPTBEADS, a melamine-formaldehyde resin and silica. The company offers performance materials comprising display, semiconductor, and inorganic materials. It also offers agricultural chemicals, such as herbicides, insecticides, fungicides, etc. for use on agricultural land, as well as in golf courses, parks, etc.; and drug substances for veterinary pharmaceuticals. In addition, the company provides pharmaceutical products, such as LIVALO, a cholesterol reduction agent; LANDEL and FINTE, a dual type calcium antagonist that blocks calcium channels; and custom manufacturing and process researching services for pharmaceutical ingredients. Further, the company provides advanced materials comprising ECOPROMOTE, an environmental harmony material; coating solutions for printable thermoelectric materials; soluble hole transport materials for organic photoelectric conversion devices; NANOFIBERGEL, a life science material; FP001, a cell culture ingredient; and SUNCONNECT, an optical material. Furthermore, it engages in the landscaping, engineering, fertilizer, plant engineering, environmental analysis, electronic materials, and transportation businesses. The company was formerly known as Nissan Chemical Industries, Ltd. and changed its name to Nissan Chemical Corporation in July 2018. Nissan Chemical Corporation was founded in 1887 and is headquartered in Tokyo, Japan.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Receive News & Ratings for NISSAN CHEM IND/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NISSAN CHEM IND/ADR and related companies with MarketBeat.com's FREE daily email newsletter.